Keywords: Sibumtramine, FDA, EMEA, Weight-loss drug, Abbott
Bad day for slimming pill sibutramine, as EMEA calls for drug’s withdrawal and US FDA for “black box” warning
Article | 22 January 2010
The weight loss drug sibutramine suffered a double whammy yesterday, after the European Medicines Agency (EMEA) called for the suspension of the marketing authorization of the products containing the compound and the USA’s Food and Drug Administration stated that the drug should carry a “black box” warning due to an increased risk of stroke and heart attack in patients with a history of cardiovascular disease.
The EMEA’s Committee for Medicinal Products for Human Use (CHMP) concluded that the risks of these medicines are greater than their benefits and recommended the suspension of marketing authorisations for these medicines across the European Union. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
